Skip to main content

Advertisement

SpringerLink
Log in

Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

The purpose of the study was clarify the effect of the cathepsin K inhibitor ONO-5334 on bone resortion markers using sustained release (SR) formulations with different pharmacokinetic (PK) patterns, and identify the optimal SR formulation. The PK profiles and pharmacodynamic effect on bone resorption markers of 4 SR candidates formulations were evaluated in healthy postmenopausal women within a randomized, 2-part, open-label crossover study. In Part A, subject received a single dose of each formulation orally in the fed state. In Part B, two selected formulations were evaluated in the fasted state. From the results from Part A, C max was reduced and plasma concentrations of ONO-5334 were sustained with all SR formulations compared with an immediate release tablet. In pharmacodynamics, the level of C-terminal telopeptide of type I collagen (CTX) in serum and urine were inhibited with SR tablets rather than with granules. C max and area under the concentration–time curve from time 0 to the last measurable time point (AUC0−t ) of SR tablets were higher than those of granules. From Part B, C max in the fasted condition was lower than that in the fed condition with two SR tablets. In contrast, C 24 h in the fasted condition was slightly higher than that in the fed condition, but AUC0−t was similar. The inhibitory effect on CTX in serum and urine may depend on the PK pattern of ONO-5334. The SR tablets was well tolerated in postmenopausal women and has the optimal SR profiles on pharmacodynamics effect on bone resortion markers and PK profile. These results suggest that SR tablets of ONO-5334 are an excellent drug candidate for osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Osteoporosis prevention, diagnosis, and therapy (2001) NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795

    Google Scholar 

  2. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T (1995) Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 206:89–96

    Article  CAS  PubMed  Google Scholar 

  3. Stoch SA, Wagner JA (2008) Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther 83:172–176

    Article  CAS  PubMed  Google Scholar 

  4. Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244

    Article  CAS  PubMed  Google Scholar 

  5. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaissé JM (1998) The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 273:32347–33252

    Article  CAS  PubMed  Google Scholar 

  6. Gelb BD, Shi GP, Chapman HA, Desnick RJ (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236–1238

    Article  CAS  PubMed  Google Scholar 

  7. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K (1998) Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:13453–13458

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I (1999) Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:1654–1663

    Article  CAS  PubMed  Google Scholar 

  9. Adami S, Supronik J, Hala T, Brown JP, Garnero P, Haemmerle S, Ortmann CE, Bouisset F, Trechsel U (2006) Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Res 21:S24

    Article  Google Scholar 

  10. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937–947

    PubMed  Google Scholar 

  11. Eastell R, Nagase S, Ohyama M, Small M, Sawyer J, Boonen S, Spector T, Kuwayama T, Deacon S (2011) Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res 26:1303–1312

    Article  CAS  PubMed  Google Scholar 

  12. Wijkmans J, Gossen J (2011) Inhibitors of cathepsin K: a patent review (2004–2010). Expert Opin Ther Pat 21:1611–1629

    Article  CAS  PubMed  Google Scholar 

  13. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541

    Article  CAS  PubMed  Google Scholar 

  14. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91

    Article  CAS  PubMed  Google Scholar 

  15. Delmas PD, Recker RR, Chesnut CH III, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792–798

    Article  CAS  PubMed  Google Scholar 

  16. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC, Fracture Intervention Trial Steering Committee, HORIZON Pivotal Fracture Trial Steering Committee (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761–1771

    Google Scholar 

  17. Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Kumar S, Dare L, Vasko-Moser JA, James IE, Blake SM, Rickard DJ, Hwang SM, Tomaszek T, Yamashita DS, Marquis RW, Oh H, Jeong JU, Veber DF, Gowen M, Lark MW, Stroup G (2007) A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40:122–131

    Article  CAS  PubMed  Google Scholar 

  19. Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, Le Bailly De Tilleghem C, Dasilva C, Rosenberg E, Leung A (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 27:2251–2258

  20. Tanaka M, Yamada H, Mori H, Kunishige A, Nishikawa S, Hashimoto Y, Shiroya T (2010) Efficacy of ONO-5334, a cathepsin K inhibitor, on bone geometry and histomorphometry in cortical bone in ovariectomized cynomolgus monkeys. J Bone Miner Res 25:S349

    Google Scholar 

  21. Jerome C, Missbach M, Gamse R (2011) Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int 22:3001–3011

    Article  CAS  PubMed  Google Scholar 

  22. Cusick T, Chen CM, Pennypacker BL, Pickarski M, Kimmel DB, Scott BB, le Duong T (2012) Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 27:524–537

    Article  CAS  PubMed  Google Scholar 

  23. Baron R (2011) Osteoporosis in 2011: osteoporosis therapy–dawn of the post-bisphosphonate era. Nat Rev Endocrinol 8:76–78

    Article  PubMed  Google Scholar 

  24. Ochi Y, Yamada H, Mori H, Nakanishi Y, Nishikawa S, Kayasuga R, Kawada N, Kunishige A, Hashimoto Y, Tanaka M, Sugitani M, Kawabata K (2011) Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone 49:1351–1356

    Article  CAS  PubMed  Google Scholar 

  25. Nagase S, Hashimoto Y, Small M, Ohyama M, Kuwayama T, Deacon S (2012) Serum and urine bone resorption markers and pharmacokinetics of cathepsin K inhibitor ONO-5334 after ascending single doses in post-menopausal women. Br J Clin Pharmacol 74:959–970

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Nagase S, Ohyama M, Hashimoto Y, Small M, Kuwayama T, Deacon S (2012) Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study. J Clin Pharmacol 52:306–318

    Article  CAS  PubMed  Google Scholar 

  27. Gandhi R, Lal Kaul C, Panchagnula R (1999) Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm Sci Technol Today 4:160–170

    Article  PubMed  Google Scholar 

  28. MacGregor EA (2009) Headache and hormone replacement therapy in the postmenopausal woman. Curr Treat Options Neurol 11:10–17

    Article  PubMed  Google Scholar 

  29. Kurumatani H (2009) Pharmacological profiles and clinical effects of oral sustained release beraprost sodium (Careload LA tablets 60 μg, Berasus LA tablets 60 μg). Folia Pharmacol Jpn 133:101–111

    Article  CAS  Google Scholar 

  30. Cristancho MA, Thase ME (2010) The role of quetiapine extended release in the treatment of bipolar depression. Adv Ther 27:774–784

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Dr. Lloyd Stevens (Scientific Investigator), Dr. Phil Evans (Principal Medical Investigator), and the staff at Pharmaceutical Profiles for their help conducting the study. We thank Dr. Gillian Pover for medical support of the study.

Conflict of interest

MT, YH, NS, NH and MY are employees of Ono Pharmaceutical Co., Ltd. Osaka, Japan. SD is employee of Ono Pharma UK Ltd., London, United Kingdom. NS engaged a formulation patent.

Author information

Authors and Affiliations

  1. Research Promotion, Ono Pharmaceutical Co., Ltd., 3-1-1, Sakurai, Shimamoto, Osaka, 618-8585, Japan

    Makoto Tanaka

  2. Pharmacokinetic Research Laboratory, Ono Pharmaceutical Co., Ltd., Ibaraki, Japan

    Yoshitaka Hashimoto & Naoki Honda

  3. Pharmaceutical Development Laboratory, Ono Pharmaceutical Co. Ltd., Osaka, Japan

    Noboru Sekiya & Masanobu Yamamoto

  4. Clinical Development, Ono Pharma UK Ltd., London, UK

    Steve Deacon

Authors
  1. Makoto Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshitaka Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noboru Sekiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoki Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Steve Deacon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masanobu Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Tanaka.

Additional information

M. Tanaka, Y. Hashimoto and N. Sekiya contributed equally to this work.

About this article

Cite this article

Tanaka, M., Hashimoto, Y., Sekiya, N. et al. Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns. J Bone Miner Metab 32, 447–454 (2014). https://doi.org/10.1007/s00774-013-0517-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-013-0517-y

Keywords

Search

Navigation